Logo image of XLO

XILIO THERAPEUTICS INC (XLO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XLO - US98422T1007 - Common Stock

0.7052 USD
+0.01 (+1.45%)
Last: 1/7/2026, 8:06:18 PM
0.71 USD
+0 (+0.68%)
Pre-Market: 1/8/2026, 7:49:32 AM
Fundamental Rating

1

XLO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. XLO may be in some trouble as it scores bad on both profitability and health. XLO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XLO has reported negative net income.
In the past year XLO has reported a negative cash flow from operations.
XLO had negative earnings in each of the past 5 years.
In the past 5 years XLO always reported negative operating cash flow.
XLO Yearly Net Income VS EBIT VS OCF VS FCFXLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

XLO has a Return On Assets (-43.75%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -43.75%
ROE N/A
ROIC N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XLO Yearly ROA, ROE, ROICXLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XLO Yearly Profit, Operating, Gross MarginsXLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

2

2. Health

2.1 Basic Checks

XLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XLO has been increased compared to 1 year ago.
XLO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for XLO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XLO Yearly Shares OutstandingXLO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XLO Yearly Total Debt VS Total AssetsXLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

XLO has an Altman-Z score of -4.57. This is a bad value and indicates that XLO is not financially healthy and even has some risk of bankruptcy.
XLO's Altman-Z score of -4.57 is on the low side compared to the rest of the industry. XLO is outperformed by 60.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.57
ROIC/WACCN/A
WACC8.56%
XLO Yearly LT Debt VS Equity VS FCFXLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

XLO has a Current Ratio of 2.20. This indicates that XLO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.20, XLO is doing worse than 73.77% of the companies in the same industry.
A Quick Ratio of 2.20 indicates that XLO has no problem at all paying its short term obligations.
XLO's Quick ratio of 2.20 is on the low side compared to the rest of the industry. XLO is outperformed by 71.51% of its industry peers.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 2.2
XLO Yearly Current Assets VS Current LiabilitesXLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

XLO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.50%, which is quite impressive.
XLO shows a strong growth in Revenue. In the last year, the Revenue has grown by 588.40%.
EPS 1Y (TTM)67.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.27%
Revenue 1Y (TTM)588.4%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%742.51%

3.2 Future

Based on estimates for the next years, XLO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.10% on average per year.
Based on estimates for the next years, XLO will show a very negative growth in Revenue. The Revenue will decrease by -19.00% on average per year.
EPS Next Y64.16%
EPS Next 2Y36.14%
EPS Next 3Y17.18%
EPS Next 5Y18.1%
Revenue Next Year492.79%
Revenue Next 2Y225.82%
Revenue Next 3Y19.19%
Revenue Next 5Y-19%

3.3 Evolution

XLO Yearly Revenue VS EstimatesXLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M
XLO Yearly EPS VS EstimatesXLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XLO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XLO Price Earnings VS Forward Price EarningsXLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XLO Per share dataXLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as XLO's earnings are expected to grow with 17.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.14%
EPS Next 3Y17.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XLO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

XILIO THERAPEUTICS INC

NASDAQ:XLO (1/7/2026, 8:06:18 PM)

Premarket: 0.71 +0 (+0.68%)

0.7052

+0.01 (+1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-09 2026-03-09/amc
Inst Owners30.02%
Inst Owner Change0%
Ins Owners0.66%
Ins Owner Change0%
Market Cap37.02M
Revenue(TTM)31.80M
Net Income(TTM)-58.49M
Analysts83.33
Price Target2.04 (189.28%)
Short Float %10.75%
Short Ratio4.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.91%
Min EPS beat(2)-98.02%
Max EPS beat(2)80.2%
EPS beat(4)2
Avg EPS beat(4)-74.2%
Min EPS beat(4)-287.6%
Max EPS beat(4)80.2%
EPS beat(8)4
Avg EPS beat(8)-88.69%
EPS beat(12)7
Avg EPS beat(12)-55.03%
EPS beat(16)10
Avg EPS beat(16)-38.88%
Revenue beat(2)1
Avg Revenue beat(2)-0.6%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)1.3%
Revenue beat(4)1
Avg Revenue beat(4)-20.89%
Min Revenue beat(4)-48.27%
Max Revenue beat(4)1.3%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-24.35%
EPS NQ rev (3m)-20%
EPS NY rev (1m)5.07%
EPS NY rev (3m)2.22%
Revenue NQ rev (1m)-15.58%
Revenue NQ rev (3m)-14.22%
Revenue NY rev (1m)5.39%
Revenue NY rev (3m)17.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.16
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.61
BVpS-0.15
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.75%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.24%
ROA(5y)-91.52%
ROE(3y)-207.32%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.93%
Cap/Sales 1.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 2.2
Altman-Z -4.57
F-Score6
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)42.95%
Cap/Depr(5y)81.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.27%
EPS Next Y64.16%
EPS Next 2Y36.14%
EPS Next 3Y17.18%
EPS Next 5Y18.1%
Revenue 1Y (TTM)588.4%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%742.51%
Revenue Next Year492.79%
Revenue Next 2Y225.82%
Revenue Next 3Y19.19%
Revenue Next 5Y-19%
EBIT growth 1Y31.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year94.76%
EBIT Next 3Y9.46%
EBIT Next 5Y12.01%
FCF growth 1Y76.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y76.64%
OCF growth 3YN/A
OCF growth 5YN/A

XILIO THERAPEUTICS INC / XLO FAQ

What is the ChartMill fundamental rating of XILIO THERAPEUTICS INC (XLO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to XLO.


Can you provide the valuation status for XILIO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to XILIO THERAPEUTICS INC (XLO). This can be considered as Overvalued.


Can you provide the profitability details for XILIO THERAPEUTICS INC?

XILIO THERAPEUTICS INC (XLO) has a profitability rating of 0 / 10.


Can you provide the financial health for XLO stock?

The financial health rating of XILIO THERAPEUTICS INC (XLO) is 2 / 10.


Can you provide the expected EPS growth for XLO stock?

The Earnings per Share (EPS) of XILIO THERAPEUTICS INC (XLO) is expected to grow by 64.16% in the next year.